MedPath

Effectiveness of metformin in reducing weight gain caused by antipsychotics

Not Applicable
Recruiting
Conditions
Schizophrenia
Registration Number
SLCTR/2010/004
Lead Sponsor
Faculty of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

1. Patients diagnosed with schizophrenia or schizoaffective disorder according to ICD-10 research criteria
2.Age > 18 years
3.Treated with olanzapine, risperidone or clozapine
4. Gained more than 10% of the pre treatment body weight

Exclusion Criteria

1. Those concurrently treated with other psychotropics known to cause weight gain, (lithium carbonate, carbamazepine, sodium valproate and antidepressants)
2. Patients too ill to consent
3. Patients previously diagnosed with diabetes
4. Pregnant patients
5. Patients with impaired renal functions before enrollment (Sample size calculation is based on an expected difference in weight of Body Weight Gain of between the 2 groups, a power of 80%, and a Type I error of 5%. Sample size required in each group=64)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
change in total body weight [Baseline, 12 weeks and 24 weeks]<br>
Secondary Outcome Measures
NameTimeMethod
Body Mass Index (BMI), waist/hip ratio, fasting blood sugar, lipid profile [Baseline, 12 weeks and 24 weeks]<br>
© Copyright 2025. All Rights Reserved by MedPath